1620545-75-6

Upstream product

• 1369594-44-4 C₁₄H₁₁Br₂FN₂O 
• 1369594-41-1 1-(4-bromo-2-fluoro-6-hydroxyphenyl)ethan-1-one 
• 1159821-56-3 2-cyclopropylthiazole 
• 1369594-45-5 C₁₄H₈Br₂FNO 
• 1620545-74-5 3,10-dibromo-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-12,12a-dihydro-6H-indolo[1,2-c][1,3]benzoxazine 
• 1620450-58-9 5-bromo-2-(5-bromoindolin-2-yl)-3-fluorophenol 
• 877385-86-9 2-cyclopropylthiazole-5-carbaldehyde 

Downstream Products

• 1613081-64-3 dimethyl((2S,2’S)-((2S,2’S)-2,2’-(5,5’-((S)-6-(2-cyclopropylthiazol-5-yl)-1-fluoro-6H-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3methyl-1oxobutane-2,1-diyl))dicarbamate 

Relevant academic research and scientific papers

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms

We describe the research that led to the discovery of compound 40 (ruzasvir, MK-8408), a pan-genotypic HCV nonstructural protein 5A (NS5A) inhibitor with a "flat" GT1 mutant profile. This NS5A inhibitor contains a unique tetracyclic indole core while maintaining the imidazole-proline-valine Moc motifs of our previous NS5A inhibitors. Compound 40 is currently in early clinical trials and is under evaluation as part of an all-oral DAA regimen for the treatment of chronic HCV infection.

HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', R 2 R 3, R 4 and R are as defined herein. The present i

THIAZOLYL-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention relates to novel Thiazolyl-Substituted Tetracyclic Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, A', R2R3, R4 and R5 are as defined herein. The present